InnoCare Pharma (09969) directors and senior executives plan to reduce their shareholding.

InnoCare Pharma (09969) announced that the company recently received a notice from the Executive Director, Chairman of the Board, and CEO Jisong Cui, Executive Director, Senior Vice President of Hematology Research and Clinical Development Renbin Zhao, and Chief Technology Officer Xiangyang Chen regarding their shareholding reduction plan. Due to personal financial needs, Jisong Cui, Renbin Zhao, and Xiangyang Chen plan to reduce their directly held Class A shares of the company from July 16, 2026 to September 30, 2026. Specifically, Jisong Cui plans to reduce a total of no more than 206,250 shares of company A shares through centralized bidding, which is not more than 0.0117% of the total share capital of the company; Renbin Zhao plans to reduce a total of no more than 50,000 shares of company A shares through centralized bidding, which is not more than 0.0028% of the total share capital of the company; Xiangyang Chen plans to reduce a total of no more than 62,500 shares of company A shares through centralized bidding, which is not more than 0.0035% of the total share capital of the company. The reduction period is from July 16, 2026 to September 30, 2026, and the total number of shares reduced by individuals does not exceed 25% of the total number of shares held directly prior to this reduction.